According to the latest report published by Credence Research, Inc. “Orthopedic Oncology Treatment Market (Treatment Type: Soft Tissue Excisions/Resections, Limb Salvage Surgery, Amputations, Adjuvant Chemotherapy, Reconstructive Surgery): Growth, Future Prospects and Competitive Analysis, 2016-2022,” the orthopedic oncology treatment market was valued at USD 1.02 Bn in 2015, and is expected to reach USD 1.12 Mn by 2023, expanding at a CAGR of 1.2% from 2016 to 2023.
Browse the full report Orthopedic Oncology Treatment: Market Growth, Future Prospects and Competitive Analysis, 2016-2023 at http://www.credenceresearch.com/report/orthopedic-oncology-treatment-market
While the management of musculoskeletal sarcoma remains one of the most significant challenges in oncology, there have been prominent improvements in the past decades. Improvement in surgical systems, nature of implants, imaging modalities, adjuvant chemotherapy have improved the treatment output to such an extent that currently 2/3rds of musculoskeletal carcinoma patients are anticipated to be long-term disease survivors and several will successfully benefit from limb salvage procedures. the field of orthopedic oncology continues to be invigorated by exhilarating research and developments that has enhanced the level of treatment and care of patients with various bone and soft-tissue tumors. Currently, most patients with primary bone sarcomas are offered limb salvage surgery without increasing the risk of survival at the sarcoma centers. Moreover, the advances in the imaging technique and surgical techniques have further improved the treatment of patients with bone and soft-tissue malignancies. Orthopedic oncologists continue to join forces with other sub-specialists to integrate advances in surgical techniques. This is especially true for the development of implants and image guided surgery.
The global orthopedic oncology treatment market on type of procedures has been segmented into soft tissue excisions/resections, limb salvage surgery, amputation, adjuvant chemotherapy and reconstructive surgery. The reconstructive surgery is further sub-segmented into hip & joint replacement and bone grafts. The reconstructive surgery has the largest share in the global orthopedic oncology treatment market. The bone grafting techniques is anticipated to grow at the highest rate during the forecast period owing to the advances in the field of prosthesis and endoprosthesis. In the base 2015, Asia Pacific was observed as the largest market for orthopedic oncology market. Large disease prevalence along with the growing healthcare ecosystem in the region has assisted the growth of the orthopedic oncology market in Asia-Pacific. Moreover, growth in the medical tourism in the region in the last decade has further fueled the market for orthopedic oncology treatment market in Asia-Pacific.
The major players operating in this market include Stryker Corporation, DePuy Synthes, Zimmer Biomet, Sanofi, Roche Holdings and others.